Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 312 across all filing types
Latest filing 2025-08-28 Earnings Release
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 1 page 233.2KB
Earnings Release Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final report for the financial year ended 30 June 2025' which is a regulatory form used in Australia to announce preliminary final results. It contains summarized financial results for the full fiscal year ending 30 June 2025, including revenues, losses, net tangible asset backing, and dividend information. The document states it is based on accounts in the process of being audited and references the Corporations Act 2001, indicating it is a formal financial announcement. The length is 2725 characters, which is relatively short and consistent with a preliminary final report announcement rather than a full annual report. Appendix 4E filings are typically classified as Earnings Releases (ER) because they provide initial key financial results for the full year but do not contain the full detailed financial statements of an Annual Report (10-K). Therefore, the document is best classified as an Earnings Release (ER).
2025-08-28 English
Full Year Statutory Accounts 46 pages 4.5MB
Regulatory Filings
2025-08-28 English
Quarterly Activities & Appendix 4C Cash Flow Reports 7 pages 547.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. It contains detailed financial data including cash flow statements for the quarter ended 30 June 2025, commentary on company activities during the quarter, and financing details. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is approximately 15,000 characters, indicating it is the full report, not just an announcement of a report. Therefore, the correct classification is 'IR' (Interim / Quarterly Report).
2025-07-30 English
Application for quotation of securities - VBS 7 pages 21.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from Vectus Biosystems Limited regarding the application for quotation of securities on the ASX. It details the issuance and conversion of options into ordinary fully paid shares, including specifics about the number of securities, issue dates, and whether they are part of an employee incentive scheme. The document is an official notice related to the listing and quotation of new securities rather than a financial report or earnings release. This type of document corresponds to announcements about share issues or capital changes, specifically the quotation of new shares resulting from option exercises. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8675 characters) and content confirm it is not a brief report publication announcement or a regulatory filing fallback.
2025-07-16 English
Cleansing Notice 1 page 223.2KB
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement from Vectus Biosystems Limited regarding the issuance of new shares following the exercise of employee options. It includes a Cleansing Notice under section 708A(5)(e) of the Corporations Act 2001, which is a regulatory compliance statement related to the share issue. The document does not contain financial statements or detailed financial data, nor is it a full report. It is an announcement about a capital change (issue of shares). Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is short and focused on the share issuance event, fitting the SHA category with high confidence.
2025-07-16 English
Notification regarding unquoted securities - VBS 7 pages 22.3KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options under an employee incentive scheme by Vectus Biosystems Limited. It includes specifics such as the number of securities issued, issue dates, security descriptions, and references to ASX listing rules. The content is a formal notification of a securities issue rather than a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital changes related to securities issuance. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (7078 characters) and detailed issuance data support this classification with high confidence.
2025-06-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.